Siren L.L.C. Has $9.06 Million Stock Holdings in Taysha Gene Therapies, Inc. $TSHA

Key Points

• Siren L.L.C. has reduced its holdings in Taysha Gene Therapies by 1.3%, selling 87,738 shares, while maintaining approximately 6.5 million shares valued at $9 million.
• Multiple institutional investors have increased their stakes in Taysha Gene Therapies, with Bank of America Corp DE growing its investment by 1,178.9% in the last quarter.
• Analysts have positively revised their price targets for Taysha Gene Therapies, with estimates ranging from $6.00 to $11.00 and an average consensus target price of $8.29.

Siren L.L.C. lessened its stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 1.3% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,514,737 shares of the company's stock after selling 87,738 shares during the quarter. Siren L.L.C. owned about 3.18% of Taysha Gene Therapies worth $9,055,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Granahan Investment Management LLC boosted its holdings in shares of Taysha Gene Therapies by 0.3% in the 1st quarter. Granahan Investment Management LLC now owns 1,640,793 shares of the company's stock valued at $2,281,000 after purchasing an additional 4,412 shares during the last quarter. Rhumbline Advisers boosted its holdings in shares of Taysha Gene Therapies by 7.0% in the 1st quarter. Rhumbline Advisers now owns 205,462 shares of the company's stock valued at $286,000 after purchasing an additional 13,383 shares during the last quarter. ProShare Advisors LLC raised its stake in shares of Taysha Gene Therapies by 32.3% in the 4th quarter. ProShare Advisors LLC now owns 59,076 shares of the company's stock valued at $102,000 after acquiring an additional 14,418 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Taysha Gene Therapies by 23.3% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 108,604 shares of the company's stock valued at $188,000 after acquiring an additional 20,551 shares during the period. Finally, Ameriprise Financial Inc. purchased a new position in shares of Taysha Gene Therapies in the 4th quarter valued at $40,000. Institutional investors and hedge funds own 77.70% of the company's stock.

Insider Activity at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 200,000 shares of the stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $3.23, for a total transaction of $646,000.00. Following the transaction, the insider owned 1,006,439 shares in the company, valued at $3,250,797.97. This represents a 16.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 3.78% of the stock is currently owned by company insiders.

Taysha Gene Therapies Trading Up 0.2%

Shares of TSHA stock traded up $0.01 during trading hours on Tuesday, reaching $3.03. 1,036,921 shares of the stock traded hands, compared to its average volume of 2,954,790. Taysha Gene Therapies, Inc. has a 1-year low of $1.05 and a 1-year high of $3.40. The business has a fifty day moving average price of $2.83 and a 200 day moving average price of $2.33. The company has a quick ratio of 12.48, a current ratio of 12.48 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $825.20 million, a PE ratio of -8.90 and a beta of 0.98.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.02). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 78.44%. The firm had revenue of $1.99 million for the quarter, compared to analyst estimates of $1.61 million. On average, equities research analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Citigroup reissued an "outperform" rating on shares of Taysha Gene Therapies in a research note on Thursday, May 29th. Wells Fargo & Company raised their target price on shares of Taysha Gene Therapies from $7.50 to $8.00 and gave the company an "overweight" rating in a research note on Wednesday, August 13th. JMP Securities raised their target price on shares of Taysha Gene Therapies from $5.00 to $6.00 and gave the company a "market outperform" rating in a research note on Thursday, May 29th. Canaccord Genuity Group raised their target price on shares of Taysha Gene Therapies from $9.00 to $11.00 and gave the company a "buy" rating in a research note on Tuesday, June 3rd. Finally, Chardan Capital lifted their price target on shares of Taysha Gene Therapies from $9.00 to $10.00 and gave the stock a "buy" rating in a research note on Tuesday, August 12th. Eight investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Taysha Gene Therapies currently has a consensus rating of "Buy" and an average target price of $8.29.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.